Actelion Ltd. | Balance Sheet

Fiscal year is January-December. All values CHF Millions.
2012
2013
2014
2015
2016
Cash & Short Term Investments
1,131
1,501
1,208
406
501
Total Accounts Receivable
413
406
400
427
446
Inventories
56
53
61
62
136
Other Current Assets
31
59
57
68
110
Total Current Assets
1,631
2,020
1,726
963
1,193
Net Property, Plant & Equipment
403
381
368
348
350
Total Investments and Advances
369
-
-
-
-
Intangible Assets
244
592
575
548
518
Other Assets
27
21
16
16
25
Total Assets
2,694
3,030
2,748
1,915
2,106
ST Debt & Current Portion LT Debt
-
-
235
-
-
Accounts Payable
91
104
74
84
83
Income Tax Payable
34
51
23
40
62
Other Current Liabilities
335
817
332
298
424
Total Current Liabilities
460
972
665
421
569
Long-Term Debt
235
235
-
-
-
Provision for Risks & Charges
470
29
62
67
66
Deferred Taxes
21
17
61
35
12
Other Liabilities
10
85
99
108
141
Total Liabilities
1,176
1,321
827
600
785
Common Equity (Total)
1,519
1,709
1,920
1,318
1,325
Total Shareholders' Equity
1,519
1,709
1,920
1,318
1,325
Total Equity
1,519
1,709
1,920
1,315
1,321
Liabilities & Shareholders' Equity
2,694
3,030
2,748
1,915
2,106
Accumulated Minority Interest
-
-
-
3
4

About Actelion

View Profile
Address
Gewerbestrasse 16
Allschwil Basel-Landschaft (Basle Country) 4123
Switzerland
Employees -
Website http://www.actelion.com
Updated 07/08/2019
Actelion Ltd. operates as a holding company with interests in developing, producing and marketing pharmaceutical drugs. It is a biopharmaceutical company, which focuses on the drug discovery, development, registration, production and commercialization of innovative drugs for diseases with significant unmet medical needs. Its portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications.